cas 100243-39-8|| where to buy (S)-3-Pyrrolidinol

Nombre del producto:(S)-3-Pyrrolidinol

IUPAC Name:(3S)-pyrrolidin-3-ol

Unidad de embalaje	Stock disponible	Precio($)
CM116538-25g	in stock	ŵưǊ
CM116538-100g	in stock	ƎǶǊ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 100243-39-8 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :100243-39-8; Fórmula molecular:C4H9NO; Punto de fusión:-; Código de sonrisas:O[C@@H]1CNCC1; Densidad:

: Número de catálogo:CM116538; Peso molecular:87.12; Punto de ebullición:; Nº Mdl:MFCD00192426; Almacenamiento:Keep in dark place, inert atmosphere, store at 2-8°C.

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.

: Selatogrel; Selatogrel is an investigational, potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being developed for the treatment of an acute myocardial infarction (AMI) in patients with a recent history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector).
This novel, self-administered emergency agent has the potential to protect heart muscle in the very early phase of an AMI – in the crucial time between symptom onset and first medical attention – so as to treat the ongoing AMI and prevent early death.